MHRA approves trofolastat for prostate cancer diagnostic imaging
Trofolastat is a prostate-specific membrane antigen-targeting agent cleared for use with Technetium-99m for cancerous lesion detection.

Trofolastat is a prostate-specific membrane antigen-targeting agent cleared for use with Technetium-99m for cancerous lesion detection.
AI can be used to help improve both disease diagnosis and treatment plans, leading to better patient outcomes.
The medical devices industry continues to be a hotbed of patent innovation. Activity is driven by increased need for homecare,...
Medical Technology is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Apple’s hearing aid software is impressive, but audiologists still matter
AngioInsight to assess AI-powered platform for cardiovascular diagnosis
NHS ups AI push with Cera software rollout for fall prediction
Apple UK update transforms AirPods into hearing aids